Vera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious immunological diseases. Its lead product candidate is atacicept, licensed from Ares Trading S.A. (affiliate of Merck KGaA), being developed for immunoglobulin A nephropathy (IgAN) and other conditions. The company also has MAU868, licensed from Novartis, and VT-109, licensed from Stanford University, in its pipeline. Vera has no approved products and has not generated revenue from product sales.
expected 2026-11-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-077442 | EDGAR | 110K words |
| 2025-02-28 | 2024-12-31 | 0000950170-25-029969 | EDGAR | 104K words |
| 2024-03-27 | 2023-12-31 | 0000950170-24-036729 | EDGAR | 105K words |
| 2023-03-28 | 2022-12-31 | 0000950170-23-010288 | EDGAR | 107K words |
| 2022-03-28 | 2021-12-31 | 0000950170-22-004701 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-10 | 2026-06-30 | 0001193125-26-342380 | EDGAR | 69K words |
| 2025-11-05 | 2025-09-30 | 0001193125-25-266881 | EDGAR | 68K words |
| 2025-08-05 | 2025-06-30 | 0000950170-25-103022 | EDGAR | 67K words |
| 2025-05-07 | 2025-03-31 | 0000950170-25-064733 | EDGAR | 64K words |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123239 | EDGAR | 67K words |
| 2024-08-08 | 2024-06-30 | 0000950170-24-094108 | EDGAR | 67K words |
| 2024-05-10 | 2024-03-31 | 0000950170-24-057292 | EDGAR | 65K words |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062139 | EDGAR | 68K words |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041399 | EDGAR | 70K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021335 | EDGAR | 69K words |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023932 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0000950170-22-016498 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-15 | 0001193125-26-391280 | EDGAR | 7K words |
| 2026-08-10 | 0001193125-26-342335 | EDGAR | 3K words |
| 2026-03-09 | 0001193125-26-098783 | EDGAR | 1K words |
| 2026-02-26 | 0001193125-26-073421 | EDGAR | 2K words |
| 2025-12-18 | 0001193125-25-323298 | EDGAR | 0K words |
| 2025-12-10 | 0001193125-25-314430 | EDGAR | 23K words |
| 2025-11-26 | 0001193125-25-300647 | EDGAR | 1K words |
| 2025-11-06 | 0001193125-25-268331 | EDGAR | 1K words |
| 2025-11-05 | 0001193125-25-265799 | EDGAR | 2K words |
| 2025-08-05 | 0001193125-25-173591 | EDGAR | 21K words |
100 total filings indexed. 73 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001831828 |
| Ticker | VERA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.veratx.com |
| Listed | 2021-05-14 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/VERA (~200 tokens, structured JSON with cryptographic provenance)